<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618137</url>
  </required_header>
  <id_info>
    <org_study_id>COPD-AUVA</org_study_id>
    <nct_id>NCT00618137</nct_id>
  </id_info>
  <brief_title>Inert Dusts and Pathology of Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Longitudinal Assessment of Clinical and Molecular Pathology of Chronic Obstructive Lung Disease and the Possible Influence of Inert Dusts in Working Volunteers of the Greater Vienna Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is the exploration of the natural course of COPD and its&#xD;
      biological background. To this end, active workers without COPD and workers in functional&#xD;
      classes GOLD 0-III are investigated by a combined clinical and molecular approach. The study&#xD;
      has been designed as a prospective, intraindividual pilot in 160 male or female volunteers of&#xD;
      the greater Vienna Area over a period of three years for each individual volunteer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint Combined assessment of clinical and molecular data obtained in three&#xD;
      sequential study visits over an investigative period of 36 months for each individual; this&#xD;
      includes, in particular, the identification of single and clustered gene functions connected&#xD;
      to deterioration or stability of pulmonary function at the end of the observation period.&#xD;
&#xD;
      Secondary endpoints Assessment of occupational and environmental exposure to primarily inert&#xD;
      fine dusts in a random subset of the strata by means of 24h-measurement of quantity and&#xD;
      quality of fine dust inhalation; Influence of intensified exposure to fine dusts due to&#xD;
      occupational conditions; Development of lung function in the five different study groups (see&#xD;
      below), particularly changes from one GOLD class into the next class;&#xD;
&#xD;
      Definition of Study Groups:&#xD;
&#xD;
      Group 1 (Control):&#xD;
&#xD;
      Healthy volunteers, age 18 to 35 yr, never smokers (n=20).&#xD;
&#xD;
      Group 2 (preferentially taxi or bus drivers; COPD °0):&#xD;
&#xD;
      Working men/women, age 18 to 65 yr, preferentially taxi drivers or bus drivers or comparable&#xD;
      occupational burden, current smokers or ex-smokers, with symptoms suggestive of COPD, yet&#xD;
      regular lung function test at rest at the time of study entry, no signs of significant other&#xD;
      diseases, in particular no signs of cardiovascular disease (n=35).&#xD;
&#xD;
      Group 3 (preferentially taxi or bus drivers; COPD °I-III):&#xD;
&#xD;
      Working men/women, preferentially taxi drivers or bus drivers or comparable occupational&#xD;
      burden, age 35 to 65 yr, current smokers or ex-smokers, with symptoms of COPD, and abnormal&#xD;
      lung function at rest at the time of study entry, no signs of significant other diseases, in&#xD;
      particular no signs of cardiovascular disease (n=35).&#xD;
&#xD;
      Group 4 (Welder; COPD °0):&#xD;
&#xD;
      Working men/women, active welders or comparable occupational burden, age 35 to 65 yr, current&#xD;
      smoker or ex-smoker, with symptoms suggestive of COPD, yet regular lung function test at&#xD;
      rest, no signs of significant other diseases, in particular no signs of cardiovascular&#xD;
      disease (n=35).&#xD;
&#xD;
      Group 5 (Welder; COPD °I-III):&#xD;
&#xD;
      Working men/women, active welders or comparable occupational burden, age 35 to 65 yr, current&#xD;
      smoker or ex-smoker, with symptoms of COPD and abnormal lung function at rest at the time of&#xD;
      study entry, no signs of significant other diseases, in particular no signs of cardiovascular&#xD;
      disease (n=35).&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  COPD °IV&#xD;
&#xD;
        -  Bronchial asthma&#xD;
&#xD;
        -  Major cardiovascular diseases, in particular stroke and myocardial infarction with&#xD;
           reduced cardiac function&#xD;
&#xD;
        -  Age &gt; 65 years&#xD;
&#xD;
        -  Acute or chronic bronchial infections, in particular bronchiectasis&#xD;
&#xD;
        -  Cancer&#xD;
&#xD;
      Study investigations&#xD;
&#xD;
      Visit 1 Visit 2 Visit 3 Clinical investigation x x x Blood drawing for laboratory testing x x&#xD;
      x Spirometry x x x Body plethysmography x x x Spiro-Ergometry x x x CT Thorax x x x&#xD;
      Bronchoscopy with transbronchial biopsy x x x Gene profiling x x x&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">160</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Transbronchial lung biopsies Blood serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample of workers from the greater Vienna area&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD °0-III&#xD;
&#xD;
          -  Workers of the greater Vienna Area&#xD;
&#xD;
          -  Current smokers or ex-smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COPD °IV&#xD;
&#xD;
          -  Bronchial asthma&#xD;
&#xD;
          -  Major cardiovascular diseases, in particular stroke and myocardial infarction with&#xD;
             reduced cardiac function&#xD;
&#xD;
          -  Age &gt; 65 years&#xD;
&#xD;
          -  Acute or chronic bronchial infection, in particular bronchiectasis&#xD;
&#xD;
          -  Cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lutz H Block, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolf Ziesche, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pulmonary Medicine, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>August 23, 2012</last_update_submitted>
  <last_update_submitted_qc>August 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rolf Ziesche</investigator_full_name>
    <investigator_title>Associated Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>Gene expression profiling</keyword>
  <keyword>Inert dusts</keyword>
  <keyword>Natural course</keyword>
  <keyword>Prospective assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

